Thaum Lub Peb Hlis 18, 2026, Zhongxin Biotechnology tshaj tawm tias US Food and Drug Administration (FDA) tau pom zoo nws qhov kev sim tshuaj (IND) daim ntawv thov rau nws cov mRNA tus neeg sib tw tshuaj IN026. INO26 yog ib qho kev txhim kho mRNA rau kev kho mob gout. Tom qab qhov kev pom zoo ntawm IND, lub tuam txhab yuav soj ntsuam kev nyab xeeb, kev ua siab ntev, cov tshuaj pharmacokinetics, thiab cov yam ntxwv ntawm cov tshuaj IN026 hauv cov neeg mob uas xav tau kev kho mob tsis zoo nyob rau theem 1 kev sim tshuaj.
Semaglutide hmoov CAS 910463-68-2
1.Peb muab
(1) Tablet
(2) Cov
(3) Capsule
(4) Txau
(5) API (Ntshiab hmoov)
(6) Pill press machine
https://www.achievechem.com/pill-xwm
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
PIB: BM-2-4-008
Semaglutide CAS 910463-68-2
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R&D Dept.-4
Peb muabSemaglutide hmoov, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia tshwj xeeb thiab cov ntaub ntawv khoom.
Khoom siv:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html
INO26 ua tiav cov txheej txheem degradation ntawm uric acid hauv vivo los ntawm kev xa mRNA encoding uric acid oxidase (UOX) rau lub siab. INO26 yog ib qho kev txhim kho mRNA kho mob rau kev kho mob gout refractory. Nws xa mRNA encoding uric acid oxidase (UOX) rau lub siab thiab siv UOX qhia los txhawb kev degradation ntawm uric acid hauv lub cev. Kev cia siab rau mRNA LNP (tus xa xov ribonucleic acid lipid nanoparticle) thev naus laus zis platform ntawm nws tus kheej tsim los ntawm Zhongxin Biotechnology thiab tsim los rau kev tswj hwm thiab ntev -lub sij hawm tswj kab mob, INO26 xav tias yuav dhau los ua lub peev xwm ua ntej hauv chav kawm mRNA protein hloov kho rau refractory gout thiab lwm yam kab mob metabolic.
Johnson&Johnson lub ntiaj teb thawj qhov ncauj IL-23R tsom peptide Icotrokinra pom zoo rau kev ua lag luam los ntawm FDA
Thaum Lub Peb Hlis 18, 2026, Johnson&Johnson tshaj tawm tias lcotrokinra (lub npe lag luam: Icotyde) tau pom zoo los ntawm FDA rau kev kho mob ntawm cov kab mob me me mus rau mob hnyav plaque psoriasis (PsO) hauv cov tub ntxhais hluas thiab cov neeg laus hnub nyoog 12 xyoos thiab laus dua. icotrokinra yog ib qho tshuaj peptide hauv qhov ncauj uas tuaj yeem tsom qhov thaiv ntawm iL23 receptor (IL-23R), nrog rau ib tus lej pM qib binding affinity rau IL-23R hauv cov menyuam yaus. Qhov no receptor yog ib qho tseem ceeb mechanism ntawm inflammatory teb ntawm plaque psoriasis thiab muaj peev xwm siv nyob rau hauv lwm yam IL-23-mediated kab mob.
Thawj kev tshawb fawb ntawm IcotrokinraProtagonist Therapeutics. Xyoo 2017, Johnson&Johnson tau ua tiav daim ntawv tso cai thiab kev sib koom tes nrog Protagonist Therapeutics los tsim thawj tiam IL-23R tshuaj. Ob tog tau nthuav dav lawv txoj kev koom tes hauv 2019 kom suav nrog thib ob - tiam IL-23R tshuaj, nrog rau tag nrho cov nyiaj pauv mus txog 1.025 billion US dollars. Xyoo 2021, Johnson&Johnson tau hloov kho nws daim ntawv cog lus kev koom tes dua thiab tau txais txoj cai thoob ntiaj teb rau ob tiam thib ob ntawm cov tshuaj Er-23R (Icotrokinra thiab JNJ-5186), nrog rau qhov txiaj ntsig siab tshaj plaws txog li 980 lab US las.
Baiyang Pharmaceutical nqis peev hauv Sihe Gene thiab ntxiv dag zog rau nws cov AS0 me me nucleic acid kev tsim kho tshiab
Thaum Lub Peb Hlis 19, 2026, Baiyang Pharmaceutical (301015. SZ) tshaj tawm tias lub tuam txhab npaj yuav kos npe rau "Daim ntawv cog lus peev" nrog Sihegen (Beijing) Biotechnology Co., Ltd. Tom qab kev nqis peev, lub tuam txhab yuav tuav 10% kev ncaj ncees ntawm Sihegen. Los ntawm qhov kev koom tes no, Baiyang Pharmaceutical muaj tswv yim locks nyob rau hauv lub ntiaj teb no thawj zaug tsis kam thiab coj mus muag txoj cai ntawm tag nrho cov kev tshawb fawb pipelines ntawm Sihegen.
Anti-sensitive oligonucleotides (ASO) thiab me me cuam tshuam RNA (siRNA) yog tam sim no ob txoj hauv kev thev naus laus zis rau cov tshuaj me me nucleic acid, ob qho tib si tswj cov noob qhia los ntawm kev tsom mRNA, ua tiav kev kho mob ntawm cov kab mob. Lub Sihe Gene tau nqis peev los ntawm Baiyang Pharmaceutical lub sijhawm no yog ib tus neeg sawv cev lag luam hauv Suav teb uas tsom mus rau kev tshawb fawb thiab kev tsim cov tshuaj ASO tshiab. Nws tau tsim thawj ASO kev tshawb fawb thiab kev loj hlob platform hauv Suav teb nrog kev ua tiav thawj lub peev xwm, tsim kom muaj kev sib tw tshwj xeeb piv rau siRNA txoj kev, thiab siv zog los txhawb qhov kev tsim kho tshiab thiab kev kho mob txhais lus ntawm cov tshuaj ASO hauv tsev.
Raws li thawj AI algorithm platform, kev hloov kho tshuaj lom neeg tshiab, thiab cov chiv xa tawm platform tsim tau zoo rau ASO sequences hauv Suav teb, Sihe Gene tau tsim cov thev naus laus zis thev naus laus zis uas ua rau muaj kev tshawb fawb thiab kev loj hlob tshiab. Tsis ntev los no, nws tus kheej tau tsim kho Chav Kawm 1 ASO cov tshuaj tshiab "SG12 Txhaj" rau kev kho tus kab mob siab B ntev tau pom zoo rau IND kev sim tshuaj vim nws muaj peev xwm tshem tawm cov kab mob zoo heev thiab ntev ntev -cov nyhuv inhibitory tshwm sim hauv cov qauv kev sim tsiaj. Nyob rau tib lub sijhawm, nws cov tshuaj tshiab nucleic acid "SG13 khoom" rau kev kho mob plawv tsis ua haujlwm tau raug xaiv ua tiav rau National Science thiab Technology Major Special Project for Innovative Drug Research and Development thaum lub sijhawm 15th Tsib Xyoo Npaj. Nws yog tam sim no nyob rau theem kev tshawb fawb preclinical thiab npaj yuav thov rau kev sim tshuaj hauv 2027.
NovoNordisk Smeaglutide 7.2mg pom zoo rau kev lag luam tawm
Thaum Lub Peb Hlis 19, 2026, Novo Nordisk tshaj tawm tias qhov siab - koob tshuaj ntawm Wegovy HD, 7.2mg ntawm semaglutide, tau pom zoo los ntawm FDA rau ntev - lub sij hawm tswj qhov hnyav ua ke nrog kev noj zaub mov tsis muaj calorie thiab ua kom muaj zog.
FDA tau muab rau Wegowy HD tus thawj coj qib National Priority Review Certificate, ua kom cov khoom lag luam tshuaj xyuas cov txheej txheem thiab qhia txog nws lub peev xwm tseem ceeb hauv kev ua tau raws li cov neeg mob xav tau thiab cov tswv yim kev noj qab haus huv hauv tebchaws hauv Tebchaws Meskas.
Qhov kev pom zoo nrawm nrawm no yog nyob ntawm cov ntaub ntawv los ntawm STEPUP qhov kev sim tshuaj ntsuam xyuas. Hauv STEPUP txoj kev tshawb fawb, kev tswj hwm 7.2mg ntawm kev txhaj tshuaj semaglutide ib zaug hauv ib lub lis piam ua rau qhov hnyav poob ntawm 20.7% hauv cov neeg rog rog, nrog kwv yees li ib -feem peb ntawm cov kev kawm tau poob ntawm 25% lossis ntau dua. Hauv Hejing Kev Tshawb Fawb Txog Cov Neeg Mob Ntshav Qab Zib Hom 2 (STEP UP T2D), 7.2mg smeglutide ua tiav qhov hnyav poob ntawm 14.1%.
Ob qhov kev sim dua ib zaug tau lees paub txog kev paub txog kev nyab xeeb thiab kev zam rau cov yam ntxwv ntawm semaglutide, thiab tag nrho cov kev ua tau zoo ntawm koob tshuaj 7.2mg tau zoo ib yam nrog cov kev sim tshuaj yav dhau los cuam tshuam txog kev tswj qhov hnyav semaglutide. Novo Nordisk cia siab tias Wegovy HD ib koob tshuaj cwj mem yuav raug tsim tawm hauv Tebchaws Meskas thaum lub Plaub Hlis 2026.
Wegowy ib zaug txhua hnub cov ntsiav tshuaj ntawm qhov ncauj (Megvii 25mg) thiab ib zaug txhaj tshuaj txhua lub lim tiam (Smeaglutide 1.7mg, 2.4mg, thiab 7.2mg) tau pom zoo rau kev lag luam los ntawm US FDA. Wegow txoj kev txhaj tshuaj txhua lub limtiam tau pom zoo los ntawm European Medicines Agency (EMA) thiab ntau lub koom haum tswj hwm thoob ntiaj teb. Wegowy cov ntsiav tshuaj ntawm qhov ncauj tam sim no tab tom tos kev pom zoo hauv khw los ntawm EMA thiab lwm lub koom haum tswj hwm.
Wegovy yog qhov tsim nyog rau cov neeg laus rog rog lossis rog rog kom txo qhov hnyav thiab ua tiav ntev - cov teebmeem poob phaus. Cov neeg mob yuav tsum muaj tsawg kawg yog ib qho hnyav txog qhov teeb meem. Cov khoom no kuj tau txais kev pom zoo los ntawm FDA rau kev siv rau cov neeg mob rog rog lossis rog rog nrog cov kab mob plawv, txo lawv txoj kev pheej hmoo ntawm cov teeb meem mob plawv loj, suav nrog kev tuag, myocardial infarction, lossis mob stroke. Tsis tas li ntawd, Wegow txhaj tshuaj yog tsim rau cov tub ntxhais hluas hnub nyoog 12 xyoos thiab siab dua uas yog neeg ruam, thiab yog siv los txo qhov hnyav tshaj thiab tswj tau ntev - lub sij hawm poob qhov hnyav. Cov khoom no kuj tau txais kev pom zoo los ntawm DA rau kev kho mob ntawm cov neeg laus metabolic dysfunction txuam nrog steatohepatitis (MASH) nrog rau nruab nrab mus rau mob siab fibrosis (lub siab caws pliav), tab sis tsis haum rau cov neeg mob cirrhosis.
